Qualitative Test for SARS-CoV-2 Antigen, Influenza A and/or Influenza B - Vietnam Registration 2403121ĐKLH/BYT-HTTB
Access comprehensive regulatory information for Qualitative Test for SARS-CoV-2 Antigen, Influenza A and/or Influenza B in Vietnam's medical device market through Pure Global AI's free database. This Risk Class TTBYT Loại C medical device is registered under number 2403121ĐKLH/BYT-HTTB and manufactured by Abbott Rapid Dx Galway. The authorized representative in Vietnam is VĂN PHÒNG ĐẠI DIỆN ABBOTT LABORATORIES GMBH TẠI THÀNH PHỐ HÀ NỘI.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 300,000+ Vietnamese medical device registrations, helping global MedTech companies navigate Vietnam MOH regulations, identify competitors, and discover partnership opportunities efficiently.
Device Details
Registration Details
2403121ĐKLH/BYT-HTTB
000.00.04.G18-240314-0001
Theo theo phụ lục
Theo phụ lục
Technical Details
The Panbio™ COVID-19/Flu A&B Panel (Nasal) is an in vitro diagnostic test for the qualitative detection of SARS-CoV-2 nucleocapsid protein and Influenza A&B nucleoprotein antigens in specimens from the nasal mid-turbinate (NMT) swab of symptomatic individuals who meet the clinical and/or epidemiological criteria for COVID-19 and/or Flu. The Panbio™ COVID-19/Flu A&B Panel (Nasal) is intended for use by trained professionals in a laboratory setting and near the patient to support the diagnosis of SARS-CoV-2 and Flu. This test is not intended for self-testing. This test is not automated. The test provides a preliminary test result. A negative result does not rule out the possibility of SARS-CoV-2 and Influenza A&B infections and should not be used as the sole basis for treatment or other control decisions. A negative result must be interpreted in conjunction with clinical observations, patient history, and epidemiological information.
Dates and Status
Nov 02, 2024